Stigma and Health is an esteemed academic journal published by the Educational Publishing Foundation in conjunction with the American Psychological Association. This journal is dedicated to advancing the understanding of stigma and its multifaceted impacts on health and well-being, encompassing a broad spectrum of disciplines including clinical psychology, public health, and mental health. Since its inception in 2020, it has garnered significant recognition, achieving a Q1 ranking in Health Policy and Public Health, and a Q2 ranking in Clinical Psychology, Psychiatry, and Social Psychology as of 2023. With both an ISSN and E-ISSN of 2376-6972 and 2376-6964 respectively, it is poised as a vital resource for researchers, professionals, and students who aim to explore the intricate relationships between stigma, mental health, and societal factors. The journal is committed to providing a platform for innovative research and discussions, thus fostering a deeper understanding of health disparities and promoting health equity. Although access is not open, its impactful findings contribute to the global discourse surrounding stigma in health contexts. For those dedicated to the important work of understanding and mitigating stigma, Stigma and Health stands as a crucial and influential publication in the field.

Welcome to AIDS PATIENT CARE AND STDS, a leading journal dedicated to the comprehensive exploration of clinical practices, research advancements, and public health strategies centered around HIV/AIDS and sexually transmitted diseases. Published by Mary Ann Liebert, Inc., this esteemed journal has been at the forefront of disseminating critical findings since 1996, contributing to a robust understanding of the complexities surrounding these global health issues. With an impressive impact factor reflected in its 2023 Q1 quartile rankings in both Infectious Diseases and Public Health, Environmental and Occupational Health, the journal stands out among its peers, ranking at the 95th percentile for Public Health and 91st percentile in Infectious Diseases. Researchers, healthcare professionals, and students will benefit from its rich content, comprehensive studies, and critical reviews that aim to improve care practices and health outcomes. With a clear commitment to fostering knowledge and collaboration in the field, AIDS PATIENT CARE AND STDS is an essential resource for those dedicated to combating these pressing health challenges.

AJAR - African Journal of AIDS Research, an esteemed publication by Taylor & Francis Ltd, stands at the forefront of research in the field of HIV/AIDS, with a specific focus on the African continent. Established in 2003 and publishing continuously through 2024, this journal serves as a crucial platform for disseminating innovative research findings aimed at addressing the challenges of HIV/AIDS. With its ISSN 1608-5906 and E-ISSN 1727-9445, AJAR is indexed in prominent databases and holds a respectable Q3 rating in major categories such as Infectious Diseases, Medicine, Public Health, and Virology as of 2023. This positions the journal as a relevant resource for scholars and medical professionals looking to stay informed on the latest developments and strategies in AIDS research. Although it is not currently an open-access journal, AJAR provides readers with valuable insights that are essential for advancing public health initiatives and infectious disease research across Africa and beyond. The journal's commitment to high-quality peer-reviewed research underscores its importance within its field, making it a vital resource for researchers, students, and policymakers alike.

International Journal of Radiation Oncology Biology Physics, published by Elsevier Science Inc, is a premier academic journal that has played a critical role in advancing the field of radiation oncology since its inception in 1975. With an impressive impact factor and recognition as a Q1 journal across multiple categories such as Cancer Research, Oncology, and Radiology, this journal serves as a vital resource for researchers, clinicians, and students dedicated to understanding and improving cancer treatment modalities. Its multifaceted scope encompasses original research, reviews, and innovative clinical studies, fostering a deeper understanding of the interplay between radiation, biology, and oncology. With a remarkable ranking in Scopus, including a top position in Radiation Physics and an elite percentile in Oncology, IJROBP remains at the forefront of scientific discovery and innovation in the management of cancer. A traditional subscription model ensures high-quality, peer-reviewed content, providing invaluable insights that continue to advance the standards of care and research in radiation oncology.

Journal of Psychosomatic Obstetrics & Gynecology, published by TAYLOR & FRANCIS LTD, is a leading open access academic journal that has been instrumental in bridging the gaps between psychosomatic health, obstetrics, and gynecology since its inception in 1982. With a commitment to disseminating high-quality research across a broad spectrum of interrelated fields, this journal is categorized in the Q2 quartile for Clinical Psychology, Obstetrics and Gynecology, Psychiatry and Mental Health, and Reproductive Medicine. The journal boasts impressive Scopus rankings, positioning it prominently at the 83rd percentile for Obstetrics and Gynecology and the 81st percentile for Clinical Psychology. This vital resource serves as a platform for researchers, clinicians, and students alike, fostering innovative discussions and advancements in understanding the psychosomatic dimensions of women’s health. With the transition to open access in 2023, the journal further enhances its reach and accessibility, ensuring that critical research findings are available worldwide, promoting informed practices and improving patient care.

MATURITAS is a leading international journal dedicated to promoting high-quality research in the fields of Obstetrics and Gynecology, and Biochemistry, Genetics, and Molecular Biology. Published by Elsevier Ireland Ltd, this prestigious journal boasts an impressive impact factor, consistently ranking in the Q1 quartile in both categories, underscoring its critical role in advancing scientific knowledge and clinical practices. Established in 1978 and spanning through to 2024, MATURITAS facilitates the dissemination of innovative findings and provides crucial insights into women's health and reproductive issues. Researchers, professionals, and students can engage with a wealth of resources, as the journal embraces a wide range of accessible options to foster scholarly communication. With ranks of #10 out of 209 in Medicine and #38 out of 221 in General Biochemistry, Genetics and Molecular Biology according to Scopus, MATURITAS remains at the forefront of research, making it an invaluable resource for those eager to contribute to and expand their understanding in these vital fields.

AIDS Research and Treatment is a premier open access journal published by HINDAWI LTD, dedicated to advancing the understanding and treatment of HIV/AIDS and related conditions. Launched in 2010, the journal has established itself as a vital resource for researchers, healthcare professionals, and students in the fields of Dermatology, Immunology, Infectious Diseases, and Public Health. With a notable 2023 impact factor reflected in its Q2 and Q3 quartile rankings across key medical categories, the journal plays a critical role in disseminating high-quality research and fostering innovation in the prevention and treatment of AIDS. It provides a wide range of open access options, enabling easier dissemination and increased visibility of research findings globally. As the landscape of HIV/AIDS research continues to evolve, AIDS Research and Treatment remains at the forefront, ensuring crucial insights and developments are shared to enhance public health outcomes.

JAIDS - Journal of Acquired Immune Deficiency Syndromes, is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamics of HIV/AIDS and its broader implications in the fields of infectious diseases and pharmacology. With an esteemed impact factor that places it in the prestigious Q1 category for both Infectious Diseases and Pharmacology (medical) as of 2023, this journal aims to provide a platform for groundbreaking research, clinical findings, and innovative therapies relevant to the management and prevention of HIV/AIDS. The journal's rigorous editorial standards and commitment to advancing knowledge make it an essential resource for researchers, healthcare professionals, and students invested in the global response to AIDS. Although the journal does not currently offer open access options, it remains instrumental in disseminating high-quality research that shapes clinical practices and policy developments in the field.

AIDS, published by Lippincott Williams & Wilkins, stands as a premier journal within the fields of immunology and infectious diseases, reflecting a distinguished history since its inception in 1987 and offering insights that shape contemporary research and practice. With an impressive impact factor and categorized in the Q1 quartile across critical areas including Immunology, Infectious Diseases, and Immunology and Allergy, the journal showcases high-quality, peer-reviewed articles that consistently contribute to the advancement of knowledge and innovation in the fight against AIDS and related conditions. Researchers and professionals will find its content invaluable, as it brings forth groundbreaking studies, novel therapeutic approaches, and comprehensive reviews that inform both clinical practices and public health policies. Although not an open access journal, it remains a vital resource for those committed to addressing one of the most pressing global health challenges of our time.

AIDS REVIEWS, published by Permanyer Publishing, is a distinguished academic journal dedicated to providing comprehensive insights into the field of AIDS research. Since its inception in 2000, the journal has served as a vital platform for disseminating knowledge on various aspects of HIV/AIDS, including prevention, treatment advancements, and socio-medical implications. With a commendable Q3 ranking in both Infectious Diseases and Medicine (miscellaneous), as well as Pharmacology (medical) in 2023, the journal has made significant strides in the academic community, covering relevant topics and emerging trends up to 2024. Although not open access, AIDS REVIEWS continues to attract contributions from leading researchers and professionals, fostering a collaborative environment aimed at improving health outcomes related to AIDS. Located in Barcelona, Spain, this journal is an essential resource for anyone dedicated to advancing their understanding of this global health challenge.